Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated July 23, 2025, reports a regulatory update regarding the Biologics License Application (BLA) for Blenrep (belantamab mafodotin-blmf). The filing addresses the treatment of relapsed or refractory multiple myeloma in patients who have received at least one prior line of therapy.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a current report focused solely on regulatory status and clinical trial outcomes.
Material Changes and Regulatory Status
- FDA Review Extension: The US Food and Drug Administration (FDA) has extended the review period for the Blenrep BLA. The new Prescription Drug User Fee Act (PDUFA) action date is scheduled for October 23, 2025.
- Reason for Extension: The extension provides the FDA time to review additional information submitted by GSK in support of the application.
- Global Approvals: Blenrep combinations are currently approved in the UK (April 2025), Japan (May 2025), Canada, Switzerland (DREAMM-8 only), and the United Arab Emirates.
- Pending Reviews: Applications are under review in the EU (positive CHMP opinion received) and China (priority review granted).
Clinical Data and Management Commentary
GSK expressed confidence in the data supporting Blenrep combinations and looks forward to ongoing constructive conversations with the FDA. The BLA is supported by pivotal Phase III trials:
- DREAMM-7 Trial: Evaluated Blenrep + bortezomib + dexamethasone (BVd) vs. daratumumab + bortezomib + dexamethasone (DVd).
- Progression-Free Survival (PFS): Median PFS was 36.6 months for BVd vs. 13.4 months for DVd (HR 0.41).
- Overall Survival (OS): Statistically significant 42% reduction in risk of death (HR 0.58). Three-year OS rate was 74% (BVd) vs. 60% (DVd).
- DREAMM-8 Trial: Evaluated Blenrep + pomalidomide + dexamethasone (BPd) vs. bortezomib + pomalidomide + dexamethasone (PVd) in heavily pre-treated patients.
- PFS: Median PFS was 32.6 months for BPd vs. 12.5 months for PVd (HR 0.49). At one year, 71% of BPd patients were alive and progression-free vs. 51% for PVd.
- OS: A positive trend was observed (HR 0.77) but was not statistically significant at the interim analysis; follow-up continues.
Risks and Contingencies
The filing includes a cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in GSK's 2024 Form 20-F and Q1 2025 results. Key risks include the uncertainty of FDA approval timelines and the potential for clinical data to be interpreted differently by regulators.
Investor Verification Checklist
- Verify the specific nature of the "additional information" requested by the FDA that necessitated the review extension.
- Monitor the October 23, 2025, PDUFA date for the final FDA decision on the US BLA.
- Review the safety and tolerability profiles of Blenrep combinations in the Summary of Product Characteristics, particularly regarding ocular toxicity and other known side effects.
- Track the status of the EU and China regulatory reviews, which are currently pending final approval.
- Assess the commercial impact of the US approval delay on GSK's oncology revenue projections for the remainder of 2025 and 2026.